PALISADE BIO, INC.

Clinical-stage IBD biotech that is exceptionally well capitalized after a $138M raise, with positive Phase 1 data on PALI-2108.

Strengths

• $133M cash (51st pct) and current ratio ~29x (98th pct) fund multiple programs
• Positive Phase 1 SAD/MAD/UC results; Phase 2 UC/CD and IND filings planned for 2026

Risks

• No revenue and continued operating losses (~$18M); product only at Phase 1/1b
• Dependent on Giiant license and clinical success of a single lead asset

Notable findings

• Exec changeRecent 8-K item 5.02 8-K ↗
• Material weakness• Failure to remediate a material weakness in internal controls over financial reporting could result in material misstatements in our consolidated financial statements
• Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC, FMR LLC
• Buying back stockNet buyback — share count -15%/yr over 4y
• Strong balance sheetStrong balance sheet — $133M cash & investments
• Notable holderHeld by 4 notable fund(s): GOLDMAN SACHS GROUP INC, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP +1 more (as of 2026-03-31)
• Insider sellingInsider selling — 2 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, last 6mo) Form 4 ↗
• Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗